ASH 2024 | Five-year analysis of the POLARIX study: Pola-R-CHP in DLBCL

So we presented the data on the five years update of the POLARIX studies, the studies that compare R-CHOP vs. Pola-R-CHP, and has shown with the two years follow-up a significant benefit for the primary endpoint, which was progression-free survival. At five years, what we observed is that this benefit was confirmed and sustained with a hazard ratio of 0.77, showing then a reduction in the risk of progression of that of about 23% for this patient. We looked at overall survival which is still not significantly different, although it’s possible that the curve may eventually separate and diverge in the future. When we look in particular at the number of deaths that are lymphoma related, they seem to be rather similar during the two, three first years of the study but tend to diverge more recently and are more deaths related to lymphoma in the R-CHOP arms and in the Pola-R-CHP arm. Again, no significant difference but a numerical difference which is trending in the right direction. No new safety signal. Again, what was published in the New England is just confirmed with a longer follow-up. In terms of patients with high-risk disease, we observed a significant benefit in terms of progression survival 10% for patients with an IPI 3-5, almost 5% difference in overall survival. Same trend for patients for high-grade B-cell lymphoma, double hit, triple hit. And for those patients with a molecularly defined ABC subtype, the difference in PFS was 25% and the difference in OS is 15%. So clearly Pola-R-CHP appears to be a standard regimen for a category of patients with an advanced stage DLBCL, IPI-2-5, and may benefit to patients with more high-risk Thank you for your attention.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.